Download
https://www.ndtvprofit.com/business/fda-pulls-up-aurobindo-pharma-for-repeated-failures-in-cgmp?utm_source=telegram&utm_medium=referral&utm_campaign=socialshare
Aurobindo unit I, unit IX were inspected and cited for CGMP deficiencies related to the manufacture of (b)(4) API, intermediates.
Share